Gerresheimer stock
GXI.DEXETRAGerresheimer AG, HealthcareISIN DE000A0LD6E6WKN A0LD6E
48Score 48 out of 100, Weak
Price and trend
83 / 100
Price history
+29% in one yearThe chart shows daily closes over 19 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 24% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 52).
The price is 4.4% below its 52-week high. Largest decline in 19 years: 87% (September 2023 to February 2026).
Chart figures for advanced users
- SMA 50$32.76
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$28.29
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)52
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$17.40
- The lowest closing price of the last twelve months.
- Resistance$36.57
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Gerresheimer AG belongs to the Medical (Instruments & Supplies) industry (Germany) and, with a market value of $1.21B, is number 39 of 44 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.57B (up 14% year on year) and a loss of $354.94M.
- For fiscal 2026, analysts expect on average revenue of $2.6B (up 0.9%) and adjusted earnings per share of $1.92 (down 13%).
Show more
- MEQIRI Score 48 out of 100 (Weak): rank 398 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- Margin fallingOperating margin −9%, average of the prior years 9.8% (to 2024).Profitability 13
- High debtDebt 2.25 times equity (latest quarter), Medical (Instruments & Supplies) median 0.45.Stability 29
- Loss-makingLoss of $443.93M over the last 12 months.Fundamentals 49
Its standout strengths are technical analysis and momentum, while capital allocation and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- weak fundamentals
What lowers it
- price near its 52-week high
Valuation
Valuation signal
Possible value trapA fair value is not meaningful here, so the signal follows the valuation grade.
Possible value trap: looks cheap, but score below 50, high risk.
Valuation metrics
The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 28 Feb 2026, revenue rose 8.9% on the twelve months before. Revenue has grown solidly since 2006, at about 7% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 18%, operating −9%, net −14%.
Debt & balance sheet
latest quarterDebt is elevated; no interest coverage is reported.
Earnings
- Next earnings
- 25 Nov 2026in 12 days
- Last reported
- 4 Nov 2026EPS reported $0.70 (expected $0.31)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 8.3% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $1.92−5.7%
- Revenue
- $2.6B−0.3%
- Earnings per share
- $2.72−8.3%
- Revenue
- $2.59B−1.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Gerresheimer
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 48
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- DENTSPLY SIRONAXRAY $1.84B46
- LeMaitre VascularLMAT $1.78B70
- Kestra Medical TechnologiesKMTS $1.7B43
- STAAR SurgicalSTAA $1.34B44
- Safilo GroupSFL.MI $1.01B61
- Dynavox GroupDYVOX.ST $784.35M67
- AngioDynamicsANGO $504.23M39
- EmbectaEMBC $364.32M63
ETFs that hold Gerresheimer
Held by 16 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF DISTLGWU | 0.24% | 0.40% | €580.62M |
| UBS MSCI EMU Small Cap UCITS ETF EUR disUEFD | 0.18% | 0.28% | €630.46M |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.16% | 0.30% | €813.64M |
Show 5 more
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.07% | 0.23% | €321.86M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.06% | 0.30% | €3.45B |
| Vanguard Germany All Cap UCITS ETF (EUR) DistributingVGER | 0.05% | 0.07% | €255.26M |
| Amundi F.A.Z. 100 UCITS ETFC006 | 0.04% | 0.15% | €104.39M |
| UBS MSCI EMU Select Factor Mix UCITS ETF EUR accUIQN | 0.03% | 0.34% | €16.96M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 30 Nov 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2024)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.